[{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panaxia's Agreement with International Pharma Neuraxpharm is Finalized","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"N\/A","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"N\/A"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira Funds","pharmaFlowCategory":"D","amount":"$1,880.0 million","upfrontCash":"Undisclosed","newsHeadline":"Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Brain Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Expands Its Business in Southeast Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Reinforces Presence in Poland with The Acquisition of Glenmark\u2019s CNS Product Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Acquires Market-Leading Buccolam\u00ae For Emergency Treatment of Epileptic Children","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Enters the Advanced Medical Cannabis Market in Germany with A Collaboration with Panaxia","therapeuticArea":"Neurology","highestDevelopmentStatus":"N\/A","country":"SPAIN","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"N\/A"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Expands Italian Product Portfolio with A Well-Established Brand From Almirall","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraxpharm Launches First Product in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$645.0 million","upfrontCash":"$140.0 million","newsHeadline":"TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI\u00ae (ublituximab-xiiy)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$645.0 million","upfrontCash":"$152.5 million","newsHeadline":"TG Therapeutics Announces European Launch of BRIUMVI\u00ae (ublituximab-xiiy)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Neuraxpharm
Through agreement, Neuraxpharm will focus on the commercialization of Briumvi (ublituximab) in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis.
Under the agreement, TG Therapeutics will commercialise Briumvi (ublituximab), the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis.
The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal, Dogmatil, Largactil.
Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of severe chronic pain.
Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be offered.
Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.
The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.
Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics and Ireland.
The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.
Ansiolin® (diazepam) is a benzodiazepine indicated to treat anxiety and other somatic or psychiatric conditions associated to anxiety syndrome, while it is also indicated for insomnia.